sorafenib has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea) | Trials (3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea) | Recent Studies (post-2010) (3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 131 | 6 | 127 |
Protein | Taxonomy | sorafenib (IC50) | 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea (IC50) |
---|---|---|---|
Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.1093 | |
Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.001 | |
Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.0626 | |
Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.1011 | |
Fibroblast growth factor receptor 4 | Mus musculus (house mouse) | 0.561 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, WC; Hartano, S; Ho, RZW; Huynh, H; Koh, TS; Le, TBU; Lee, P; Prawira, A; Teo, XQ; Thng, CH; Tran, A; Vu, TC | 1 |
1 other study(ies) available for sorafenib and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
Article | Year |
---|---|
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Contrast Media; Humans; Kinetics; Liver Neoplasms; Magnetic Resonance Imaging; Mice, SCID; Neovascularization, Pathologic; Perfusion; Phenylurea Compounds; Pyrimidines; Receptors, Fibroblast Growth Factor; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |